Correspondence 0001193125-24-265243 from PMV Pharmaceuticals, Inc. (PMVP) (CIK 0001699382) (PMVP)
PMV Pharmaceuticals, Inc. (PMVP) (CIK 0001699382)
Date: Nov. 25, 2024 · CIK: 0001699382 · Accession: 0001193125-24-265243
AI Filing Summary & Sentiment
File numbers found in text: 333-283349
Letter
Acceleration Request
November 25, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re:
PMV Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed November 20, 2024
File No. 333-283349
Acceleration Request
Requested Date:
Wednesday, November 27, 2024
Requested Time:
4:30 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, PMV Pharmaceuticals, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan J. Baier at (212) 497-7736.
[Signature page follows]
Securities and Exchange Commission
November 25, 2024
Page 2
Sincerely,
PMV PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request November 25, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: PMV Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 20, 2024 File No. 333-283349 Acceleration Request Requested Date: Wednesday, November 27, 2024 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, PMV Pharmaceuticals, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan J. Baier at (212) 497-7736. [Signature page follows] Securities and Exchange Commission November 25, 2024 Page 2 Sincerely, PMV PHARMACEUTICALS, INC. /s/ Michael Carulli Michael Carulli Chief Financial Officer cc: Kenneth A. Clark, Tony Jeffries, and Megan J. Baier, Wilson Sonsini Goodrich & Rosati, P.C.